January 31, 2015 11:30 PM ET

Healthcare Providers and Services

Company Overview of Biodesix, Inc.

Company Overview

Biodesix, Inc., a molecular diagnostic company, develops patient care improvement products for personalized medicine. It offers VeriStrat, a clinically validated serum test for advanced non-small cell lung cancer patients; and Clinical Laboratory Improvement Amendments (CLIA) Laboratory to test clinical samples in a CLIA-accredited setting. The company also offers ProTS, a set of analysis algorithms that enable the use of matrix-assisted, laser desorption ionization mass spectrometry for clinical diagnostics. In addition, it designs and implements biomarker development process. Biodesix, Inc. was founded in 2005 and is headquartered in Boulder, Colorado.

2970 Wilderness Place

Suite 100

Boulder, CO 80301

United States

Founded in 2005





Key Executives for Biodesix, Inc.

Chief Executive Officer and Director
Age: 55
Chief Financial Officer
Chief Medical Officer
Age: 55
Chief Technology Officer
Vice President of Legal & Regulatory Affairs
Compensation as of Fiscal Year 2014.

Biodesix, Inc. Key Developments

AVEO Oncology and Biodesix, Inc. Announces Presentation of Results from A Retrospective Exploratory Analysis Using Veristrat

AVEO Oncology and Biodesix, Inc. announced the presentation of results from a retrospective exploratory analysis using VeriStrat, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEO's HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSA) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC). The results, presented in a poster session (abstract #8195) at the 2014 Congress of the European Society for Medical Oncology (ESMO), suggest that VeriStrat may be selective of positive clinical response for ficlatuzumab plus gefitinib over gefitinib alone. A total of 188 patients were enrolled in a randomized Phase 2 study (P6162) designed to compare the combination of ficlatuzumab and gefitinib with gefitinib alone in treatment-naïve Asian patients with non-small cell lung adenocarcinoma. For this retrospective exploratory analysis, 180 serum samples were assigned a VeriStrat label of either "Good" (VSG) or "Poor" (VSP) (VSG=145, VSP=35). While the study failed to demonstrate improved overall survival (OS) or progression-free survival (PFS) over gefitinib alone in the intent-to-treat population, the addition of ficlatuzumab to gefitinib provided significant clinical benefit to the VSP subgroup. No benefit was observed in the VSG subgroup in either OS (Median 24.7 mo for ficlatuzumab + gefitinib [n=69] vs not reached for gefitinib alone [n=76]; HR 1.18, p=0.492) or PFS (Median 5.6 mo for ficlatuzumab + gefitinib vs 5.6 mo for gefitinib alone; HR 1.06, p=0.753). Despite the small sample sizes, similar patterns in OS and PFS based on VeriStrat stratification were also observed in patients with known EGFR mutations (n=71) and VSP classification (n=11). Based on these data, in April 2014, AVEO and Biodesix(R) entered into a worldwide agreement to develop and commercialize ficlatuzumab with a Biodesix companion diagnostic test. As part of this agreement, AVEO and Biodesix plan to conduct a confirmatory Phase 2 study using a Biodesix VeriStrat "Poor" classification as a selective biomarker for the combination of ficlatuzumab and an EGFR-TKI, versus an EGFR TKI alone, in previously untreated, EGFR mutation-positive patients with advanced non-small-cell lung cancer. The study is expected to initiate before year-end.

Biodesix, Inc. Announces Board Appointments

Biodesix, Inc. announced two key additions to its leadership team. Richard Hockett, M.D., assumes the role of chief medical officer, overseeing the regulatory, medical and clinical strategy for Biodesix' expanding pipeline of new products. Jasmine Gruia-Gray, Ph.D., has been named vice president of strategic marketing, a role in which she will engage the marketplace on the clinical value of using noninvasive diagnostics to guide targeted therapy for patients. Dr. Hockett, a board certified clinical pathologist and champion of personalized medicine, brings three decades of experience in applying biomarkers to clinical medicine. He most recently served as chief medical officer for CombiMatrix and before that as chief medical officer for Affymetrix. Meanwhile, Dr. Gruia-Gray has joined Biodesix to lead marketing efforts for the company and its novel diagnostic products. Prior to joining Biodesix, Jasmine held marketing leadership roles at Affymetrix and Thermo Fisher Scientific (formerly Dionex Corp.) where she engaged scientific thought leaders to enhance the corporate brand and brought the 'voice of the customer' inside the company.

Biodesix, Inc. Presents at BIOWEST Conference 2014, Sep-10-2014 09:45 AM

Biodesix, Inc. Presents at BIOWEST Conference 2014, Sep-10-2014 09:45 AM. Venue: Marriot City Center, Denver, Colorado, United States. Speakers: David Brunel, CEO.

Similar Private Companies By Industry

Company Name Region
CarePoint Health Medical Group, LLC United States
Banner Health United States
St. Mary's Catholic Home United States
Donor Network Of Arizona United States
Genesis Medical Center, Inc United States

Recent Private Companies Transactions

Private Placement
December 31, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biodesix, Inc., please visit www.biodesix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.